Chicago Equity Partners LLC raised its position in Nektar Therapeutics (NASDAQ:NKTR) by 24.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,110 shares of the biopharmaceutical company’s stock after buying an additional 10,465 shares during the quarter. Chicago Equity Partners LLC’s holdings in Nektar Therapeutics were worth $3,238,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the business. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of Nektar Therapeutics in the second quarter valued at $137,000. Flagship Harbor Advisors LLC purchased a new position in shares of Nektar Therapeutics in the second quarter valued at $142,000. Raymond James Financial Services Advisors Inc. grew its position in shares of Nektar Therapeutics by 68.7% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 4,290 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 1,747 shares in the last quarter. Meristem LLP purchased a new position in shares of Nektar Therapeutics in the second quarter valued at $225,000. Finally, Cambridge Investment Research Advisors Inc. grew its position in shares of Nektar Therapeutics by 27.0% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 4,784 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 1,018 shares in the last quarter. Hedge funds and other institutional investors own 92.72% of the company’s stock.
In related news, Director R Scott Greer sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $67.39, for a total transaction of $673,900.00. Following the completion of the transaction, the director now directly owns 140,333 shares in the company, valued at $9,457,040.87. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jeffrey Robert Ajer sold 6,750 shares of the business’s stock in a transaction dated Thursday, September 20th. The stock was sold at an average price of $56.76, for a total value of $383,130.00. Following the transaction, the director now owns 15,750 shares of the company’s stock, valued at $893,970. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 96,000 shares of company stock valued at $5,825,680. 4.31% of the stock is owned by company insiders.
Nektar Therapeutics stock opened at $34.02 on Friday. Nektar Therapeutics has a 52 week low of $31.37 and a 52 week high of $111.36. The company has a debt-to-equity ratio of 0.13, a current ratio of 19.67 and a quick ratio of 19.55. The stock has a market cap of $6.22 billion, a P/E ratio of -61.85 and a beta of 2.91.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. Nektar Therapeutics had a return on equity of 174.70% and a net margin of 65.69%. The business had revenue of $27.80 million during the quarter, compared to analysts’ expectations of $26.08 million. During the same period in the previous year, the business earned $0.37 earnings per share. The firm’s revenue was down 81.8% on a year-over-year basis. As a group, equities research analysts predict that Nektar Therapeutics will post 3.57 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the company. TheStreet cut Nektar Therapeutics from a “c” rating to a “d+” rating in a research report on Wednesday. ValuEngine cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 2nd. Cowen set a $86.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a research report on Thursday. HC Wainwright reiterated a “hold” rating and issued a $47.00 price target on shares of Nektar Therapeutics in a research report on Monday, November 5th. Finally, Zacks Investment Research upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research report on Monday, July 16th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. Nektar Therapeutics currently has a consensus rating of “Buy” and an average target price of $79.55.
Nektar Therapeutics Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
See Also: Float
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.